stockrow
Monday 9 November 2026
Export IVVD’s income statement to Excel — free account
Invivyd, Inc.
IVVDInvivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024.
- Revenue
- +21.2%
- EPS
- −16.7%
- Free cash flow
- −226.9%
Quarter to June 2026, against a year earlier
0.56
0.03
−5.08%
Follow IVVD
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 25 | 53 | 58 | +110.5% | 60 | 87 | 230 | +62.7% | |
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | 93.63 | 92.99 | 92.23 | +93.0 pt | ||||||
| EBT | — | — | — | — | (65) | (227) | (241) | (199) | (170) | (52) | (107) | (4.3%) | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (669.42) | (98.25) | (183.90) | (98.2) pt | ||||||
| Net income | — | 0 | — | — | (65) | (227) | (241) | (199) | (170) | (52) | (107) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.31 | 0.18 | n/m | |||||
| Earnings | — | — | — | — | (18.10) | (5.32) | (2.23) | (1.81) | (1.43) | (0.30) | (0.33) | (56.0%) | ||||||
| Cash flow | — | — | — | — | (4.04) | (4.33) | (2.03) | (1.58) | (1.44) | (0.34) | (0.34) | (39.1%) | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.02) | (0.01) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | (4.04) | (4.34) | (2.05) | (1.59) | (1.44) | (0.34) | (0.34) | (39.1%) | ||||||
| Book value | — | — | — | — | (18.08) | 13.09 | 3.29 | 1.62 | 0.57 | 1.40 | 0.57 | n/m | ||||||
| Shares, m | — | — | — | — | 4 | 43 | 108 | 110 | 119 | 172 | 243 | +116.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 7.96 | 3.07 | 4.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.77 | 1.76 | 0.99 | 1.3 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 3.72 | 0.33 | 1.9 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.10 | (3.41) | (0.18) | (1.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (15) | (185) | (220) | (173) | (170) | (58) | (108) | +31.9% | |||||
| Capex | — | — | — | — | — | 0 | (2) | (1) | 0 | 0 | (1) | +16.6% | ||||||
| Free cash flow | — | — | — | — | (15) | (185) | (222) | (174) | (171) | (58) | (110) | +32.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 104 | 555 | 352 | 175 | 39 | 213 | 151 | +15.4% | |||||
| Net debt | — | — | — | — | (115) | (591) | (372) | (201) | (69) | (227) | (160) | +14.5% | ||||||
| Shareholders’ equity | — | — | — | — | (65) | 558 | 356 | 177 | 68 | 242 | 181 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (111.29) | (61.50) | (48.11) | (64.88) | (94.75) | (25.83) | (69.69) | +85.5 pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (233.82) | (334.92) | (233.8) pt | ||||||
| ROE | — | — | — | — | (26.51) | (92.05) | (52.81) | (74.48) | (138.71) | (33.96) | (95.89) | (7.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 103 | 86 | 95 | 100 | 122 | — | +4.3% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.25 | 0.44 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Invivyd, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | Compare |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| MDWD MediWound Ltd. | $184.0M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $182.5M | — (loss-making) | — (loss-making) | +190.24% (above 0%: growing) | n/m | +43.48% (above 0%: growing) | 100.00% | (39.57%) | Compare |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| WHWK Whitehawk Therapeutics, Inc. | $178.4M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | Compare |
| UPB Upstream Bio, Inc. | $176.9M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| IVVD Invivyd, Inc. | $166.0M | — (loss-making) | — (loss-making) | +21.20% (above 0%: growing) | n/m | −226.89% (below 0%: shrinking) | 91.09% | (320.76%) | |
| BBOT BridgeBio Oncology Therapeutics, Inc | $163.6M | — (loss-making) | — | — | n/m | −88.78% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $181.5M | — | — | +33.48% | — | −28.47% | 94.80% | (216.59%) |
Pay and ownership Proxy statement filed 6 April 2026
Ownership
Directors and executive officers, together
12.25%
Entities affiliated with RA Capital Management, L.P.
9.99%
Entities affiliated with Janus Henderson Group plc
8.98%
Entities affiliated with BVF Inc.
8.84%
Entities affiliated with Perceptive Advisors LLC
7.70%
Adimab, LLC
7.16%
Entities affiliated with Maverick Capital, Ltd.
6.71%
Entities affiliated with Point72 Asset Management, L.P.
5.89%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement